Vectura Group plc is a product development company. The Company focuses on the development of pharmaceutical therapies for the treatment of airways-related diseases (airways diseases). The Company has eight products marketed by its partners and a portfolio of drugs in clinical development, a number of which have been licensed to pharmaceutical companies. Its portfolio comprises partnered and licensed marketed products, as well as branded and generic investigational drugs. It has various products in the pipeline, which include VR588, VR942, VR475, VR465, VR096, VR647, VR179, VR736, VR876, NVA237, QVA149, VR315, VR506 and VR632. Its marketed products include Ultibro Breezhaler, Seebri Breezhaler, AirFluSal Forspiro, ADVATE and Adept. Its licensed products include Anoro Ellipta, Relvar Ellipta/Breo Ellipta and Incruse Ellipta. It also has a range of technology platforms, which include formulation technologies, such as PowderHale and ParticleMAX, and device technology, such as GyroHaler.